Home » Stocks » GlycoMimetics

GlycoMimetics, Inc. (GLYC)

Stock Price: $3.23 USD 0.01 (0.31%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 154.15M
Revenue (ttm) 9.00M
Net Income (ttm) -49.72M
Shares Out 47.72M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $3.23
Previous Close $3.22
Change ($) 0.01
Change (%) 0.31%
Day's Open 3.22
Day's Range 3.16 - 3.33
Day's Volume 439,491
52-Week Range 1.82 - 6.72

More Stats

Market Cap 154.15M
Enterprise Value 7.49M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 47.72M
Float 37.66M
EPS (basic) -1.15
EPS (diluted) -1.14
FCF / Share -1.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.02M
Short Ratio 7.91
Short % of Float 5.35%
Beta 2.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.13
PB Ratio 1.05
Revenue 9.00M
Operating Income -51.65M
Net Income -49.72M
Free Cash Flow -44.34M
Net Cash 146.66M
Net Cash / Share 3.07
Gross Margin 100.00%
Operating Margin -573.93%
Profit Margin -552.40%
FCF Margin -492.65%
ROA -18.41%
ROE -30.66%
ROIC -2,754.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.25*
(186.38% upside)
Low
4.00
Current: $3.23
High
15.00
Target: 9.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---0.0220.0715.033.9915.263.81
Revenue Growth----99.91%33.56%276.37%-73.83%300.04%-
Gross Profit---0.0220.0715.033.9915.263.81
Operating Income-61.39-51.50-33.93-31.91-12.78-11.14-10.613.64-6.08
Net Income-57.89-48.27-33.28-31.81-12.77-11.12-10.613.66-6.11
Shares Outstanding43.2541.0429.4021.2619.0118.451.200.930.93
Earnings Per Share-1.34-1.18-1.13-1.50-0.67-0.60-8.870.33-6.58
Operating Cash Flow-51.98-43.33-29.77-29.73-8.24-4.28-15.54-10.4713.85
Capital Expenditures-0.14-0.13-0.29-0.70-0.27-0.21-0.08-0.32-0.18
Free Cash Flow-52.13-43.46-30.06-30.44-8.51-4.49-15.62-10.7913.67
Cash & Equivalents15821012440.0946.8055.202.3117.3728.17
Total Debt3.62--------
Net Cash / Debt15521012440.0946.8055.202.3117.3728.17
Assets16821512942.3948.4657.265.2818.4228.91
Liabilities13.779.378.887.097.996.462.385.8920.45
Book Value15420512035.3040.4750.802.9112.538.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GlycoMimetics, Inc.
Country United States
Employees 57
CEO Rachel K. King

Stock Information

Ticker Symbol GLYC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GLYC
IPO Date January 10, 2014

Description

GlycoMimetics, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.